MHLW Requires Expert Panel Members To Disclose Special Interests With Makers
This article was originally published in PharmAsia News
Executive Summary
The Advanced Medical Technology Advisory Committee at the Ministry of Health, Labor and Welfare June 17 decided on new rules requiring expert panel members to disclose financial ties with drug or device makers whose products are under review. It ruled that if members or their relatives have received more than ¥5 million in donations or contract payments in the past three years, they should not attend review meetings for the drugs or devices. If the amount is between ¥5 million and ¥500,000, the member is allowed to attend discussion sessions, and below ¥500,000, he or she will be able to attend final summary sessions. MHLW defines the payments as consulting and instruction fees on patent and trademarks, speech fees and authoring compensations. The Ministry asks advisory board members and relatives to self claim the maximum amount received (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.